Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by AntibeTribeon Feb 13, 2020 4:53pm

178 Views

Post# 30688103

RE:it seems delay is the reason for pullback.

mingzhu wrote: Do not shoot messengers. we need all info, positive or negative.This is only way not to lose money. i emailed to IR Christina about patents, no answer yet. I take no answer as the "answer". i do not think this new delay will be long, maybe one month or so. we will get FE in March.

What delay are you talking about exactly?

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload